TuHURA Biosciences (HURA)

• Market cap: $123M
• 1 day: -1.23%
• 5 days: -6.98%
• 1 month: 0.42%
• 3 months: 3%
• 6 months: -42.86%
• Year to date: -41.61%
• 1 year: -65.37%
• 5 years: -99.91%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Employees: 19